Finally, two secondary publications were identified on IL-6 inhibitor therapy in sJIA and polycourse JIA, which reported HRQoL data as primary endpoint after a mean publication time of 102 months [36,48]. This evidence concerns the gene IL6 and juvenile idiopathic arthritis.